Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Brain Cell Find Points to New Therapies

April 14, 2014 9:57 am | News | Comments

Scientists have gained new understanding of the role played by a key molecule that controls how and when nerve and brain cells are formed- a process that allows the brain to develop and keeps it healthy. Read more...          

TOPICS:

Report: GSK Bribed Doctors in Poland

April 14, 2014 9:41 am | News | Comments

The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. The British drug company already faces corruption probes in China and Iraq. Read more...          

TOPICS:

Cell Models Screen Novel Meds to Regulate Body Clock

April 11, 2014 1:53 pm | News | Comments

The consequences of modern life - shift work, cell phone addiction, and travel across time zones - all disturb internal clocks found in the brain where they regulate sleep and throughout the body where they regulate physiology and metabolism. Read more...

TOPICS:
Advertisement

Target Promising in Asthma and Cancer

April 11, 2014 1:35 pm | News | Comments

In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies. Read more...

Collaboration Advances Use of Antibody Drug Conjugates

April 11, 2014 1:23 pm | News | Comments

PolyTherics Ltd. announced an extension to its ThioBridge antibody drug conjugate (ADC) collaboration with MacroGenics Inc., a U.S. biotechnology company developing innovative medicines utilizing its next generation antibody technologies. Read more...

TOPICS:

Expression of Tumor Suppressor Linked to Breast Cancer Survival

April 11, 2014 1:18 pm | News | Comments

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014. Read more...

TOPICS:

Study Findings May Drive Parkinson’s Treatment Research

April 11, 2014 12:51 pm | News | Comments

Scientists at Johns Hopkins University and the Institute for Cell Engineering may have discovered how the most common genetic cause of Parkinson’s disease destroys brain cells and devastates many patients worldwide. Read more...  

TOPICS:

After Setback, Impax Resubmits Parkinson’s NDA

April 11, 2014 12:36 pm | News | Comments

Impax Pharmaceuticals, a division of Impax Laboratories Inc., announced today the resubmission of Impax's NDA for Rytary (IPX066) to the FDA. IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease. Read more...

TOPICS:
Advertisement

Inhibiting Lactate Production Halts Tumor Growth

April 11, 2014 11:00 am | News | Comments

A research team has found that targeting the enzyme responsible for the final step of glucose metabolism not only halts tumor growth in non-small-cell lung cancer, but also leads to the regression of established tumors. Read more...       

TOPICS:

Yeast Provides Genetic Clues to Drug Response

April 11, 2014 10:45 am | News | Comments

Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us. Read more...   

TOPICS:

AbbVie's Hep C Regimen Posts Promising Phase 3 Results

April 11, 2014 10:36 am | News | Comments

AbbVie announced that in two Phase 3 studies, adult, non-cirrhotic patients with chronic genotype 1 hepatitis C virus infection receiving the investigational regimen with ribavirin (RBV) for 12 weeks achieved sustained virologic response rates 12 weeks post-treatment of about 96%. Read more...

TOPICS:

Judge Enforces Generic Frova Settlement in Favor of Mylan

April 11, 2014 10:12 am | News | Comments

Mylan Inc. confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan, settling patent litigation in connection with Mylan's generic version of Frova. Read more...   

TOPICS:

Sovaldi Continues to Excel in Trials with Hep C, Advanced Liver Disease

April 11, 2014 10:01 am | News | Comments

Gilead Sciences Inc. announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease. Read more...

TOPICS:

Governor Backs Medical Marijuana Trials

April 11, 2014 9:41 am | by Kathleen Foody | News | Comments

Georgia Gov. Nathan Deal on Thursday announced two separate efforts to pursue clinical trials on a cannabis-based drug that has shown promise in helping children who suffer from seizure disorders. Read more...           

TOPICS:

Promising Agents Burst Through 'Superbug' Defenses

April 10, 2014 3:26 pm | News | Comments

In the fight against "superbugs," scientists have discovered a class of agents called metallopolymers that can make some of the most notorious strains vulnerable to the same antibiotics that they once handily shrugged off. Read more...    

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading